Matt Gline, Roivant CEO (John Sciulli/Getty Images for GLG)

As Roivant read­ies for a UC clash with Mer­ck, CEO Matt Gline is can­did about keep­ing a com­pet­i­tive edge

Roivant CEO Matt Gline is get­ting ready for a de­vel­op­ment show­down with Mer­ck and its new­ly ac­quired ul­cer­a­tive col­i­tis drug from Prometheus Bio­sciences.

On Thurs­day …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.